{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:47:33Z","timestamp":1787161653146,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:00:00Z","timestamp":1555113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","award":["Creative Pioneering Researchers Program"],"award-info":[{"award-number":["Creative Pioneering Researchers Program"]}],"id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korean government","award":["2018 Brain Korea (BK) 21 Plus"],"award-info":[{"award-number":["2018 Brain Korea (BK) 21 Plus"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Unlike chyloperitoneum associated with clinical conditions including cancer, cirrhosis, and traumatic surgery, calcium channel blocker (CCB)-associated chyloperitoneum is rarely discussed in comprehensive studies on chyloperitoneum. We aimed to investigate the prevalence and characteristics of CCB-associated chyloperitoneum in peritoneal dialysis (PD) patients. The MEDLINE, Embase, CENTRAL, CiNii, and RISS databases were systematically searched for clinical studies on CCB-associated chyloperitoneum in PD patients published up to 31 July 2018. A total of 17 studies (four cohort studies, one case series, and 12 case reports) were selected. Eight CCBs, namely amlodipine, benidipine, diltiazem, lercanidipine, manidipine, nifedipine, nisoldipine, and verapamil, were reported to be associated with chyloperitoneum; manidipine and lercanidipine were the most frequently reported. The average prevalence of chyloperitoneum for lercanidipine was 25.97% in three cohort studies, two of which had a moderate or high risk of bias. Most of the studies revealed chyloperitoneum development within 4 days of initiation of CCB therapy and chyloperitoneum disappearance within 24 h of CCB withdrawal. The results of this study emphasise on the need for awareness among healthcare professionals regarding CCB-associated chyloperitoneum in PD patients. Further studies elucidating the causality and clinical implication of CCB-associated chyloperitoneum are needed.<\/jats:p>","DOI":"10.3390\/ijerph16081333","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T11:15:58Z","timestamp":1555326958000},"page":"1333","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review"],"prefix":"10.3390","volume":"16","author":[{"given":"Seungyeon","family":"Kim","sequence":"first","affiliation":[{"name":"College of Pharmacy &amp; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Mi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Korea"},{"name":"Department of Pharmaceutical Medicine and Regulatory Sciences, Colleges of Medicine and Pharmacy, Yonsei University, Incheon 21983, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongyoon","family":"Kwon","sequence":"additional","affiliation":[{"name":"College of Pharmacy &amp; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejin","family":"Yoo","sequence":"additional","affiliation":[{"name":"College of Pharmacy &amp; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hoi","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Seoul National University Boramae Medical Center, Seoul 07610, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euni","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy &amp; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ndt\/gfw433","article-title":"Hypertension in dialysis patients: A consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)","volume":"32","author":"Sarafidis","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2015.05.001","article-title":"US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"66","author":"Saran","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1053\/j.ajkd.2003.08.028","article-title":"Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients","volume":"42","author":"Griffith","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1046\/j.1523-1755.2002.00355.x","article-title":"Calcium channel blocker use and mortality among patients with end-stage renal disease","volume":"61","author":"Kestenbaum","year":"2002","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jamcollsurg.2011.01.010","article-title":"Atraumatic Chylous Ascites: Systematic Review on Symptoms and Causes","volume":"212","author":"Steinemann","year":"2011","journal-title":"J. Am. Coll. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/archsurg.1967.01330150031006","article-title":"The surgical significance of chylous ascites","volume":"95","author":"Vasko","year":"1967","journal-title":"Arch. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.7326\/0003-4819-96-3-358","article-title":"Evaluation and management of chylous ascites","volume":"96","author":"Press","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/apt.14284","article-title":"Review article: The diagnostic approach and current management of chylous ascites","volume":"46","author":"Lizaola","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3747\/pdi.2011.00049","article-title":"Aliskiren-induced chyloperitoneum in a patient on peritoneal dialysis","volume":"32","author":"Saka","year":"2012","journal-title":"Perit. Dial. Int."},{"key":"ref_10","first-page":"1171","article-title":"Manidipine hydrochloride induced peritoneal fluid turbidity in two patients on continuous peritoneal dialysis","volume":"24","author":"Yoshimoto","year":"1991","journal-title":"Ther. Apher. Dial."},{"key":"ref_11","first-page":"90","article-title":"Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis","volume":"50","author":"Yoshimoto","year":"1998","journal-title":"Clin. Nephrol."},{"key":"ref_12","first-page":"624","article-title":"Clinical case: Peritoneal dialysis patient with cloudy peritoneal fluid following administration of calcium antagonists","volume":"31","author":"Lopez","year":"2011","journal-title":"Nefrologia"},{"key":"ref_13","first-page":"C50","article-title":"Amlodipine induced chylous ascites in a patient undergoing peritoneal dialysis: A case report","volume":"3","author":"Gupta","year":"2016","journal-title":"Ann. Appl. Biosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/089686080902900314","article-title":"Peritonitis remains the major clinical complication of peritoneal dialysis: The London, UK, peritonitis audit 2002\u20132003","volume":"29","author":"Davenport","year":"2009","journal-title":"Perit. Dial. Int."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-156-1-201201030-00006","article-title":"Distinguishing case series from cohort studies","volume":"156","author":"Dekkers","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_17","unstructured":"(2018, June 28). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses 2000. Available online: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mohammadi, S., Jalaludin, M.Y., Su, T.T., Dahlui, M., Azmi Mohamed, M.N., and Abdul Majid, H. (2019). Determinants of Diet and Physical Activity in Malaysian Adolescents: A Systematic Review. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16040603"},{"key":"ref_19","unstructured":"World Health Organization-Uppsala Monitoring Centre (2018, June 28). The Use of the WHO-UMC System for Standardised Case Causality Assessment. Available online: https:\/\/www.who-umc.org\/media\/2768\/standardised-case-causality-assessment.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5414\/CNP74217","article-title":"Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis","volume":"74","author":"Hsiao","year":"2010","journal-title":"Clin. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1093\/ndt\/gfl269","article-title":"Cloudy dialysate due to lercanidipine","volume":"21","author":"Topal","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/089686080802800615","article-title":"Lercanidipine-induced chyloperitoneum in patients on peritoneal dialysis","volume":"28","author":"Yang","year":"2008","journal-title":"Perit. Dial. Int."},{"key":"ref_24","first-page":"377","article-title":"Turbid acellular peritoneal fluid and the use of calcium antagonists in peritoneal dialysis","volume":"33","year":"2013","journal-title":"Nefrologia"},{"key":"ref_25","first-page":"1553","article-title":"A case of continuous ambulatory peritoneal dialysis with significantly increased ultrafiltration and peritoneal fluid turbidity by Manidipine hydrochloride","volume":"26","author":"Kugiyama","year":"1993","journal-title":"Ther. Apher. Dial."},{"key":"ref_26","first-page":"1185","article-title":"Manidipine hydrochloride-induced chyloperitoneum in a patient on continuous ambulatory peritoneal dialysis","volume":"27","author":"Kato","year":"1994","journal-title":"Ther. Apher. Dial."},{"key":"ref_27","first-page":"1179","article-title":"Three cases of continuous ambulatory peritoneal dialysis with chylous peritoneal dialysate","volume":"28","author":"Fujii","year":"1995","journal-title":"Ther. Apher. Dial."},{"key":"ref_28","first-page":"383","article-title":"Manidipine hydrochloride-induced chyloperitoneum in a cadaver renal transplant patient on continuous ambulatory peritoneal dialysis","volume":"28","author":"Tsurusaki","year":"1995","journal-title":"Ther. Apher. Dial."},{"key":"ref_29","first-page":"1013","article-title":"A Case of Drug-Induced Chylous Ascites in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis","volume":"18","author":"Roh","year":"1999","journal-title":"Kidney. Res. Clin. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2008.334","article-title":"Calcium channel blocker-induced chylous ascites in peritoneal dialysis","volume":"75","author":"Tsao","year":"2009","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3747\/pdi.2010.00277","article-title":"Cloudy Peritoneal Fluid Attributable to Non-Dihydropyridine Calcium Channel Blocker","volume":"32","author":"Ram","year":"2012","journal-title":"Perit. Dial. Int."},{"key":"ref_32","first-page":"683","article-title":"Non-infectious cloudy peritoneal fluid secondary to lercanidipine","volume":"34","year":"2014","journal-title":"Nefrologia"},{"key":"ref_33","first-page":"6","article-title":"Possible role of Lercanidipine in Chiloperitoneum occurrence in CAPD: A case-report","volume":"35","author":"Nicotera","year":"2018","journal-title":"G. Ital. Nefrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.13070\/rs.en.1.995","article-title":"Chyloperitoneum post peritonitis and the role of calcium channel blockade in an infant","volume":"1","author":"Mallett","year":"2014","journal-title":"Research"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jvir.2015.09.022","article-title":"Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Chylothorax and Chylous Ascites in Cirrhosis: A Case Report and Systematic Review of the Literature","volume":"27","author":"Tsauo","year":"2016","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00404-009-1211-0","article-title":"Chylous ascites in gynecologic malignancies: Cases report and literature review","volume":"281","author":"Baiocchi","year":"2010","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0002-9270(02)04268-5","article-title":"Chylous ascites","volume":"97","author":"Cardenas","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2165\/00003495-200464170-00011","article-title":"Manidipine: A review of its use in the management of hypertension","volume":"64","author":"McKeage","year":"2004","journal-title":"Drugs"},{"key":"ref_39","first-page":"5","article-title":"The pharmacological properties of lipophilic calcium antagonists","volume":"2","year":"1998","journal-title":"Blood. Press. Suppl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jvs.2005.11.064","article-title":"Diagnosis and management of primary chylous ascites","volume":"43","author":"Campisi","year":"2006","journal-title":"J. Vasc. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hep.1840060214","article-title":"Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites","volume":"6","author":"Jungst","year":"1986","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jcpt.12555","article-title":"Lercanidipine-induced chylous ascites: Case report and literature review","volume":"42","author":"Basualdo","year":"2017","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/8\/1333\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:45:14Z","timestamp":1760186714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/8\/1333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,13]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["ijerph16081333"],"URL":"https:\/\/doi.org\/10.3390\/ijerph16081333","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,13]]}}}